Pharmacotherapy for squamous-cell carcinoma of the head and neck

Bibliography

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts and Figures 2008. American Cancer Society, Atlanta, Ga; 2008
   Google Scholar
• Fakhry C, Westra WH, Li S, Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9
   PubMed Web of Science ®Google Scholar
• Jamal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Argiris A, Brockstein BE, Haraf DJ, Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004;10:1956-62
   PubMed Web of Science ®Google Scholar
• Posner MR, Lorch JH, Goloubeva O, Oropharyngeal cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival. J Clin Oncol 2010;28(7S): abstract 5525
   Google Scholar
• Bernier J, Cooper JS, Pajak TF, Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005;27:843-50
   PubMed Web of Science ®Google Scholar
• Lee NY, de Arruda FF, Puri DR, A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006;66:966-74
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78
   PubMed Web of Science ®Google Scholar
• Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55
   PubMed Web of Science ®Google Scholar
• Bernier J, Domenge C, Eschwege F, Chemo-Radiotherapy, as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck cancer patients after surgery: results of the EORTC Phase III Trial 22931 [Abstract]. Int J Radiat Oncol Biol Phys 2001;51:(3 suppl 1):A-1
   Google Scholar
• Cooper JS, Pajak TF, Forastiere A, Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? Head Neck 1998;20:588-94
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C, for EORTC 24971/TAX 323 Study Group: cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-704
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR, Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1707-15
   Web of Science ®Google Scholar
• Dietz A, Rudat V, Dreyhaupt J, Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol 2009;266:1291-300
   PubMed Web of Science ®Google Scholar
• Curtin NJ, Hughes AN. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol 2001;2:298-306
   PubMed Web of Science ®Google Scholar
• Pivot X, Raymond E, Laguerre B, Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 2001;85:649-55
   PubMed Web of Science ®Google Scholar
• Hitt R, Jimeno A, Rodriguez-Pinilla M, Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. Br J Cancer 2004;91:2005-11
   PubMed Web of Science ®Google Scholar
• Bentzen JD, Hansen HS. Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region. Head Neck 2007;29:47-51
   PubMed Web of Science ®Google Scholar
• Rabinowits G, Bhupalam L, Miller DM, Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck. Am J Med Sci 2010;339:148-51
   PubMed Web of Science ®Google Scholar
• Martinez-Trufero J, Isla D, Adansa JC, Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010;102:1687-91
   PubMed Web of Science ®Google Scholar
• Grandis RJ, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284-92
   PubMed Web of Science ®Google Scholar
• Grandis RJ, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7
   PubMed Web of Science ®Google Scholar
• Vermorken J, Mesia R, Vega V, Cetuximab extends survival of patients with recurrent or metastatic HNSCC when added to first line platinum based therapy-results of a randomised phase III (EXTREME) study [abstract]. J Clin Oncol 2007;25:6091
   Google Scholar
• Herbst RS, Arquette M, Shin DM, Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-87
   PubMed Web of Science ®Google Scholar
• Baselga J, Trigo JM, Bourhis J, Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-77
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-54
   PubMed Web of Science ®Google Scholar
• Buentzel J, de Vries A, Micke O. Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer. J Clin Oncol 2007;25:6077
   Web of Science ®Google Scholar
• Belon J, Irigoyen A, Rodriguez I, Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck [abstract]. J Clin Oncol 2005;23:5563
   Web of Science ®Google Scholar
• Stewart JS, Cohen EE, Licitra L, Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27:1864-71
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85
   PubMed Web of Science ®Google Scholar
• Siu LL, Soulieres D, Chen EX, Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007;25:2178-83
   PubMed Web of Science ®Google Scholar
• Kim ES, Kies MS, Glisson BS, Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2006;24(Suppl):5521
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00424255
   Google Scholar
• Kondo N, Tsukuda M, Ishiguro Y, Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2010;23:957-63
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Berrier A, Robinson M, Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). ASCO 2010 Abstract No: 5505
   Google Scholar
• Seiwert TY, Clement PM, Cupissol D, BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study. ASCO 2010 Abstract No: 5501
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00454779
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00446446
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00460265
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00820248
   Google Scholar
• Bastholt L, Specht L, Jensen K, A novel fully human monoclonal antibody against epidermal growth factor receptor (EGFR). First clinical and FDG-PET imaging results from a phase I/II trial conducted by the Danish Head and Neck Cancer Study Group (DAHANCA) in patients with squamous cell carcinoma of the head and neck (HNSCC). Proc ASCO-05. Abstract 5530
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00382031
   Google Scholar
• Ramakrishnan MS, Eswaraiah A, Crombet T. Nimotuzumab a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009;1:41-8
   PubMed Web of Science ®Google Scholar
• Rojo F, Gracias E, Villena N. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res 2010;16:2474-82
   Google Scholar
• Saura C, Baselga J, Herbst R, Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): an open-label exploratory study [abstract]. J Clin Oncol 2009;27(15S): abstract 6023
   Google Scholar
• Karamouzis MV, Friedland D, Johnson R, Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): An interim analysis [abstract]. J Clin Oncol 2007;25:6049
   Google Scholar
• Gibson MK, Kies M, Kim S, Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: an updated report [abstract]. J Clin Oncol 2009;27(15S): abstract 6049
   Google Scholar
• Machiels JP, Henry S, Zanetta S, Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010;28:21-8
   PubMed Web of Science ®Google Scholar
• Choong NW, Kozloff M, Taber D, Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs 2010;28:677-83
   PubMed Web of Science ®Google Scholar
• Elser C, Siu LL, Winquist E, Phase II Trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007;25:3766-73
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00494182
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00939627
   Google Scholar
• Ciardiello F, Caputo R, Damiano V, Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-56
   PubMed Web of Science ®Google Scholar
• Available from: http://www.omicsonline.org/ArchiveJCST/2009/December/03/JCST1.52.php
   Google Scholar
• Aissat N, Le Tourneau C, Ghoul A, Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008;62:305-13
   PubMed Web of Science ®Google Scholar
• Jimeno A, Kulesza P, Wheelhouse J, Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007;96:952-9
   PubMed Web of Science ®Google Scholar
• Czerninski R, Amornphimoltham P, Patel V, Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila Pa) 2009;2:27-36
   PubMed Web of Science ®Google Scholar
• Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11:6924-32
   PubMed Web of Science ®Google Scholar
• Brooks HD, Glisson B, Lu C, Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2009;27(15S):, abstract 6022
   PubMedGoogle Scholar
• Available from: http://www.omicsonline.org/ArchiveJCST/2009/December/03/JCST1.52.php
   Google Scholar
• Koppikar P, Choi SH, Egloff AM, Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 2008;14:4284-91
   PubMed Web of Science ®Google Scholar
• Barnes CJ, Ohshiro K, Rayala SK, Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007;13:4291-9
   PubMed Web of Science ®Google Scholar
• Galer GE, Corey CL, Wang Z, Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck 2010; DOI: 10.1002/hed.21419
   Google Scholar
• Leeman-Neill RJ, Wheeler SE, Singh SV, Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009; 30:1848-56
   PubMed Web of Science ®Google Scholar
• Li X, Wang H, Lu X, Di B. STAT3 blockade with shRNA enhances radiosensitivity in Hep-2 human laryngeal squamous carcinoma cells. Oncol Rep 2010;23:345-53
   PubMed Web of Science ®Google Scholar
• Gu F, Ma Y, Zhang Z, Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 2010;23:671-6
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer 2009;100:1379-84
   PubMed Web of Science ®Google Scholar
• Chung CH, Aulino J, Muldowney NJ, Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2010;21:864-70
   PubMed Web of Science ®Google Scholar
• Hickinson DM, Klinowska T, Speake G, AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res 2010;16:1159-69
   PubMed Web of Science ®Google Scholar
• Boyle JO, Hakim J, Koch W, The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53:4477-80
   PubMed Web of Science ®Google Scholar
• Brennan JA, Boyle JO, Koch WM, Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712-17
   PubMed Web of Science ®Google Scholar
• Ganly I, Kirn D, Eckhardt G, A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000;6:798-806
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Khuri F, Ganly I, Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-98
   PubMed Web of Science ®Google Scholar
• Khuri FR, Nemunaitis J, Ganly I, A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85
   PubMed Web of Science ®Google Scholar
• Sobol RE, Merritt JA, Hood J, Advexin p53 gene therapy for recurrent squamous cell carcinoma of the head and neck (SCCHN): Safety and efficacy results of multicenter, multinational Phase II clinical trials. Proceedings of the 95th Annual meeting of American Association for Cancer Research 2004. 45 Abstract LB-331
   Google Scholar
• Zengel P, Ramp D, Mack B, Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis. BMC Cancer 2010;10:92
   PubMed Web of Science ®Google Scholar
• Dias JD, Liikanen I, Guse K, Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin Cancer Res 2010;16:2540-9
   PubMed Web of Science ®Google Scholar
• Baba Y, Kato Y, Ogawa K. Inostamycin prevents malignant phenotype of cancer: inhibition of phosphatidylinositol synthesis provides a therapeutic advantage for head and neck squamous cell carcinoma. Cell Biol Int 2010;34:171-5
   PubMed Web of Science ®Google Scholar
• Kondo N, Tsukuda M, Kimura M, Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma. Oncol Rep 2010;23:355-63
   PubMed Web of Science ®Google Scholar